Daniel L. Clemens

Daniel L. Clemens

Auto-generated profile, based on publicly available information

Daniel L. Clemens

Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2019 in ACS Nano
Verified
Journal Article
Closed access
TMTianxing Man
Tianxing Man
XZXiongfeng Zhu
Xiongfeng Zhu
YCYu Ting Chow
Yu Ting Chow
EDEmma R. Dawson
Emma R. Dawson
XWXimiao Wen
Ximiao Wen
PCPei-Yu Chiou
Pei-Yu Chiou

10 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DCDaniel L Clemens
Daniel L Clemens
BLBai-Yu Lee
Bai-Yu Lee
ASAleidy Silva
Aleidy Silva
BDBarbara Jane Dillon
Barbara Jane Dillon
SMSaša Masleša-Galić
Saša Masleša-Galić
MHMarcus A. Horwitz
Marcus A. Horwitz
Shorter, more effective treatments for tuberculosis (TB) are urgently needed. While many TB drugs are available, identification of the best regimens is challenging because of the large number of possible drug-dose combinations. We have found consistently that responses of cells or whole animals to drug-dose stimulations fit a parabolic response surface (PRS), allowing us to identify and optimize the best drug combinations by testing only a small fraction of the total search space. Previously, we used PRS methodology to identify three regimens (PRS Regimens I–III) that in murine models are much more effective than the standard regimen used to treat TB. However, PRS Regimens I and II are unsuitable for treating drug-resistant TB and PRS Regimen III includes an experimental drug. Here, we use PRS methodology to identify from an expanded pool of drugs new highly effective near-universal drug regimens comprising only approved drugs. We evaluated combinations of 15 different drugs in a human macrophage TB model and identified the most promising 4-drug combinations. We then tested 14 of these combinations in Mycobacterium tuberculosis-infected BALB/c mice and chose for PRS dose optimization and further study the two most potent regimens, designated PRS Regimens IV and V, consisting of clofazimine (CFZ), bedaquiline (BDQ), pyrazinamide (PZA), and either amoxicillin/clavulanate (AC) or delamanid (DLM), respectively. We then evaluated the efficacy in mice of optimized PRS Regimens IV and V, as well as a 3-drug regimen, PRS Regimen VI (CFZ, BDQ, and PZA), and compared their efficacy to PRS Regimen III (CFZ, BDQ, PZA, and SQ109), previously shown to reduce the time to achieve relapse-free cure in mice by 80% compared with the Standard Regimen (isoniazid, rifampicin, PZA, and ethambutol). Efficacy measurements included early bactericidal activity, time to lung sterilization, and time to relapse-free cure. PRS Regimens III–VI all rapidly sterilized the lungs and achieved relapse-free cure in 3 weeks (PRS Regimens III, V, and VI) or 5 weeks (PRS Regimen IV). In contrast, mice treated with the Standard Regimen still had high numbers of bacteria in their lungs after 6-weeks treatment and none achieved relapse-free cure in this time-period. We have identified three new regimens that rapidly sterilize the lungs of mice and dramatically shorten the time required to achieve relapse-free cure. All mouse drug doses in these regimens extrapolate to doses that are readily achievable in humans. Because PRS Regimens IV and V contain only one first line drug (PZA) and exclude fluoroquinolones and aminoglycosides, they should be effective against most TB cases that are multidrug resistant (MDR-TB) and many that are extensively drug-resistant (XDR-TB). Hence, these regimens have potential to shorten dramatically the time required for treatment of both drug-sensitive and drug-resistant TB. If clinical trials confirm that these regimens dramatically shorten the time required to achieve relapse-free cure in humans, then this radically shortened treatment has the potential to improve treatment compliance, decrease the emergence of drug resistance, and decrease the healthcare burden of treating both drug-sensitive and drug-resistant TB.

5 January 2024 in Mucosal Immunology
Verified
Journal Article
Open access
AOAngelica M. Olmo-Fontanez
Angelica M. Olmo-Fontanez
JSJulia M. Scordo
Julia M. Scordo
ASAlyssa Schami
Alyssa Schami
AGAndreu Garcia-Vilanova
Andreu Garcia-Vilanova
PPPaula A. Pino
Paula A. Pino
JTJordi B. Torrelles
Jordi B. Torrelles
The elderly population is highly susceptible to developing respiratory diseases, including tuberculosis, a devastating disease caused by the airborne pathogen Mycobacterium tuberculosis (M.tb) that kills one person every 18 seconds. Once M.tb reaches the alveolar space, it contacts alveolar lining fluid (ALF), which dictates host-cell interactions. We previously determined that age-associated dysfunction of soluble innate components in human ALF leads to accelerated M.tb growth within human alveolar macrophages. Here we determined the impact of human ALF on M.tb infection of alveolar epithelial type cells (ATs), another critical lung cellular determinant of infection. We observed that elderly ALF (E-ALF)-exposed M.tb had significantly increased intracellular growth with rapid replication in ATs compared to adult ALF (A-ALF)-exposed bacteria, as well as a dampened inflammatory response. A potential mechanism underlying this accelerated growth in ATs was our observation of increased bacterial translocation into the cytosol, a compartment that favors bacterial replication. These findings in the context of our previous studies highlight how the oxidative and dysfunctional status of the elderly lung mucosa determines susceptibility to M.tb infection, including dampening immune responses and favoring bacterial replication within alveolar resident cell populations, including ATs, the most abundant resident cell type within the alveoli.

27 November 2018 in ACS Infectious Diseases
Verified
Journal Article
Closed access
DCDaniel L. Clemens
Daniel L. Clemens
BLBai-Yu Lee
Bai-Yu Lee
SPSheba Plamthottam
Sheba Plamthottam
MTMichael V. Tullius
Michael V. Tullius
RWRuining Wang
Ruining Wang
MHMarcus A. Horwitz
Marcus A. Horwitz

1 December 2019 in Structure
Verified
Journal Article
Closed access
XYXue Yang
Xue Yang
DCDaniel L. Clemens
Daniel L. Clemens
BLBai-Yu Lee
Bai-Yu Lee
YCYanxiang Cui
Yanxiang Cui
Z. Hong ZhouZ. Hong Zhou
Z. Hong Zhou
MHMarcus A. Horwitz
Marcus A. Horwitz

18 September 2019 in Advanced Therapeutics
Verified
Journal Article
Open access
PDF file
MHMarcus A. Horwitz
Marcus A. Horwitz
DCDaniel L. Clemens
Daniel L. Clemens
BLBai‐Yu Lee
Bai‐Yu Lee
Tuberculosis (TB) is a major health problem that causes more deaths worldwide than any other single infectious disease. Current multidrug therapy for tuberculosis is exceedingly lengthy, leading to poor drug adherence, and consequently the emergence of drug resistance. Hence, much more rapid treatments are needed. Experimentally identifying the most synergistic drug combinations among available drugs is complicated by the astronomical number of possible drug‐dose combinations. This problem is dealt with by the use of an artificial‐intelligence‐enabled parabolic response surface platform in conjunction with an in vitro Mycobacterium tuberculosis–infected macrophage cell culture assay amenable to high‐throughput screening. This strategy allows rapid identification of the most effective drug‐dose combinations by testing only a small fraction of the total drug‐dose efficacy response surface. The same platform is then used to optimize the in vivo doses of each drug in the most potent regimens. Thus, regimens are identified that are dramatically more effective than the Standard Regimen in treating TB in a mouse model—a model broadly predictive of drug efficacy in humans. The most effective regimens reported herein shorten the duration of treatment required to achieve relapse‐free cure by 80% and are suitable for treating both drug‐sensitive and most drug‐resistant cases of tuberculosis.